It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HALO’s FA Score shows that 1 FA rating(s) are green whileKZIA’s FA Score has 0 green FA rating(s), and MNKD’s FA Score reflects 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HALO’s TA Score shows that 4 TA indicator(s) are bullish while KZIA’s TA Score has 4 bullish TA indicator(s), and MNKD’s TA Score reflects 4 bullish TA indicator(s).
HALO (@Biotechnology) experienced а +5.54% price change this week, while KZIA (@Biotechnology) price change was +0.36% , and MNKD (@Biotechnology) price fluctuated +7.87% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +6.06%. For the same industry, the average monthly price growth was +21.50%, and the average quarterly price growth was +21.34%.
HALO is expected to report earnings on Nov 10, 2025.
MNKD is expected to report earnings on Nov 11, 2025.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
HALO | KZIA | MNKD | |
Capitalization | 7.67B | 9.25M | 1.14B |
EBITDA | 705M | -26.77M | 82.6M |
Gain YTD | 37.084 | -6.554 | -42.457 |
P/E Ratio | 15.00 | N/A | 33.64 |
Revenue | 1.08B | 2.31M | 298M |
Total Cash | 748M | N/A | 182M |
Total Debt | 1.51B | N/A | 47.2M |
HALO | KZIA | MNKD | ||
---|---|---|---|---|
OUTLOOK RATING 1..100 | 23 | 83 | 5 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | 45 Fair valued | 39 Fair valued | |
PROFIT vs RISK RATING 1..100 | 36 | 100 | 65 | |
SMR RATING 1..100 | 12 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 42 | 38 | 85 | |
P/E GROWTH RATING 1..100 | 87 | 100 | 98 | |
SEASONALITY SCORE 1..100 | 75 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MNKD's Valuation (39) in the Biotechnology industry is in the same range as KZIA (45) and is somewhat better than the same rating for HALO (79). This means that MNKD's stock grew similarly to KZIA’s and somewhat faster than HALO’s over the last 12 months.
HALO's Profit vs Risk Rating (36) in the Biotechnology industry is in the same range as MNKD (65) and is somewhat better than the same rating for KZIA (100). This means that HALO's stock grew similarly to MNKD’s and somewhat faster than KZIA’s over the last 12 months.
HALO's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for MNKD (100) and is significantly better than the same rating for KZIA (100). This means that HALO's stock grew significantly faster than MNKD’s and significantly faster than KZIA’s over the last 12 months.
KZIA's Price Growth Rating (38) in the Biotechnology industry is in the same range as HALO (42) and is somewhat better than the same rating for MNKD (85). This means that KZIA's stock grew similarly to HALO’s and somewhat faster than MNKD’s over the last 12 months.
HALO's P/E Growth Rating (87) in the Biotechnology industry is in the same range as MNKD (98) and is in the same range as KZIA (100). This means that HALO's stock grew similarly to MNKD’s and similarly to KZIA’s over the last 12 months.
HALO | KZIA | MNKD | |
---|---|---|---|
RSI ODDS (%) | 2 days ago61% | 2 days ago89% | N/A |
Stochastic ODDS (%) | 2 days ago66% | 2 days ago81% | 2 days ago88% |
Momentum ODDS (%) | N/A | 2 days ago88% | 2 days ago79% |
MACD ODDS (%) | N/A | 2 days ago90% | 2 days ago79% |
TrendWeek ODDS (%) | 2 days ago76% | 2 days ago81% | 2 days ago81% |
TrendMonth ODDS (%) | 2 days ago75% | 2 days ago88% | 2 days ago78% |
Advances ODDS (%) | 2 days ago79% | 4 days ago81% | 3 days ago81% |
Declines ODDS (%) | 15 days ago68% | 2 days ago88% | 9 days ago80% |
BollingerBands ODDS (%) | 2 days ago60% | 2 days ago83% | 2 days ago90% |
Aroon ODDS (%) | 2 days ago75% | 2 days ago71% | 2 days ago77% |